Metformin, a drug prescribed for patients with type 2 diabetes, has potential efficacy in enhancing antitumor immunity; however, the detailed underlying mechanisms remain to be elucidated. Therefore, we aimed to identify the inhibitory molecular mechanisms of metformin on programmed death ligand 1 (PD-L1) expression in cancer cells and programmed death 1 (PD-1) expression in immune cells.

中文翻译：

---

二甲双胍抑制癌细胞中的 PD-L1 表达和免疫细胞中癌症诱导的 PD-1 表达，以促进抗肿瘤免疫。

二甲双胍是一种治疗2型糖尿病患者的药物，具有增强抗肿瘤免疫力的潜在功效；然而，详细的基本机制仍有待阐明。因此，我们的目的是确定二甲双胍对癌细胞中程序性死亡配体1（PD-L1）表达和免疫细胞中程序性死亡1（PD-1）表达的抑制分子机制。